Please wait while the formulary information is being retrieved.
BREYANZI CD4 COMPONENT (2OF 2) (lisocabtagene maraleucel, CD4 component, 2 of 2)
- diffuse large B-cell lymphoma
- follicular lymphoma
- primary mediastinal large B-cell lymphoma
- None
Contraindicated
- None
Severe
Moderate
- None
- None
Contraindicated
- None
Severe
Moderate
- None
BREYANZI CD4 COMPONENT (2OF 2) (lisocabtagene maraleucel, CD4 component, 2 of 2)
- diffuse large B-cell lymphoma
- follicular lymphoma
- primary mediastinal large B-cell lymphoma
- None
- None
More Frequent
Severe
Less Severe
- None
- None
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- None
Less Severe
- None
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
None
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- This medication may cause a serious (even fatal) reaction called cytokine release syndrome-CRS. Careful monitoring and prompt treatment may decrease your risk. Before treatment with this medication, tell your doctor your medical history, especially of any current/recent infection.<br /><br />Tell your doctor right away if you have any symptoms of CRS such as high fever, trouble breathing, chills/shaking chills, severe nausea/vomiting/diarrhea, severe muscle/joint pain, very low blood pressure, dizziness/lightheadedness. Serious nerve problems can occur after treatment with lisocabtagene maraleucel. Tell your doctor right away if you have drowsiness, seizure(s), mental/mood changes (such as confusion, anxiety, memory loss), or trouble with reading, writing, speaking, or understanding.<br /><br /> To receive this medication in the United States, you must understand, agree to, and carefully follow the requirements of the Breyanzi REMS Program. If you live in Canada or any other country, consult your doctor and pharmacist for your country's regulations.
Formulary Reference Tool